•  
  •  
  •  
  •  

2023-02-07 22:50:51

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Astral Ltd posts consolidated net profit of Rs. 93 crores in Q3FY23
  • Nova Iron and Steel Ltd Q3 FY23 loss at Rs. 14.77 crores
  • Tai Industries Ltd Q3 FY2023 profit at Rs. 2.19 crore
  • Jayatma Industries Ltd Q3 FY2023 profit at Rs. 2.84 lakhs
  • Odyssey Corporation Ltd Q3 FY23 consolidated profit up at Rs. 64.83 lakhs

Keywords Selected:  INE376G01013

Research

  • Biocon Limited - Generics & research grow; biosimilar stagnates - ICICI Securities
  • Q4FY22 Result Update – Biocon Ltd - ICICI Direct
  • Biocon - Q4FY22 First Cut - ICICI Direct
  • Q3FY22 Result Update - Biocon Ltd - ICICI Direct
  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Foundation Wins the Prestigious 'IHW Gold Award for Diseases Screening Initiative of the Year' for 2022
  • Biocon Biologics Statement on Complete Response Letter from USFDA
  • Biocon Biologics recognized as a Company with Great Managers, Two Managers conferred with individual 'Great Managers Award 2022'
  • Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India
  • Shreehas Tambe appointed as Managing Director & CEO of Biocon Biologics Ltd
  • Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
  • Biocon Limited enters into a commercialization agreement with Zentiva in Europe
  • Biocon Ranks at No. 8 in 'Global Top Employers' List by the U.S. Science Magazine
  • U.S. FDA Issues a CRL for the Biologics License Application for Insulin Aspart
  • Biocon Biologics Insulins Facility in Malaysia Receives EU GMP Certification
  • Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
  • Biocon gets 3 observations from US FDA for Site 3 at Hyderabad
  • Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
  • University of Glasgow officially Opens Mazumdar Shaw Advance Research Centre
  • HPRA Completes Audit of Biocon Biologics New mAbs Drug Substance Facility in Bengaluru
  • Biocon Ltd recommends final dividend of Rs. 0.50
  • Biocon Biologics' Insugen® awarded a 3 year contract by Ministry of Health, Malaysia
  • University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
  • Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh
  • ICRA places Biocon's ratings on watch
  • Biocon Limited - Long-term rating placed on 'Watch Developing', short-term rating reaffirmed
  • Biocon Biologics to acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
  • Biocon Pharma receives approval for ANDA from USFDA
  • Biocon Biologics Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

Latest Post

  • Astral Ltd posts consolidated net profit of Rs. 93 crores in Q3FY23
  • Nova Iron and Steel Ltd Q3 FY23 loss at Rs. 14.77 crores
  • Tai Industries Ltd Q3 FY2023 profit at Rs. 2.19 crore
  • Jayatma Industries Ltd Q3 FY2023 profit at Rs. 2.84 lakhs
  • Odyssey Corporation Ltd Q3 FY23 consolidated profit up at Rs. 64.83 lakhs


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022